Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Maia – page 32

691 clinical trials in Maia, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Maia at a glance
691
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

691 trials in Maia

Open in trial search

Phase III Study Comparing FOLFOX Plus Panitumumab Followed by FOLFIRI Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Followed by FOLFIRI Plus Panitumumab in Wild-Type RAS Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Asociacion Grupo Tratamiento De Tumores Digestivos
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Cytisinicline
  • Sponsor:Achieve Life Sciences Inc.
Countries:PortugalPortugal
  • Participants:18–64 years · Healthy volunteers
  • Substances:Nicorandil
  • Sponsor:Auxilius Pharma Sp. z o.o.
Countries:PortugalPortugal
  • Participants:18–64 years · Healthy volunteers
  • Substances:Ruxolitinib
  • Sponsor:Bluepharma Industria Farmaceutica S.A.

Single‑dose Bioavailability of Gliclazide Modified‑Release Tablets in Healthy Volunteers (Type 2 Diabetes)

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · Healthy volunteers
  • Substances:Gliclazide
  • Sponsor:Institut De Recherches Internationales Servier IRIS
Countries:PortugalPortugal
  • Participants:18–64 years · Healthy volunteers
  • Substances:Empagliflozin
  • Sponsor:Tecnimede-Sociedade Tecnico-Medicinal S.A.
Countries:PortugalPortugal
  • Participants:18–64 years · Healthy volunteers
  • Substances:Apixaban
  • Sponsor:Laboratorios Cinfa S.A.
Countries:PortugalPortugal
  • Participants:18–64 years · Healthy volunteers
  • Substances:Tofacitinib
  • Sponsor:Bluepharma Industria Farmaceutica S.A.

Evaluation of Safety and Efficacy of Zilovertamab Vedotin and Nemtabrutinib in Aggressive and Indolent B-cell Malignancies

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Nemtabrutinib
  • Sponsor:Merck Sharp & Dohme LLC
Countries:PortugalPortugal
  • Participants:18–64 years · Healthy volunteers
  • Substances:Ulipristal Acetate
  • Sponsor:Laboratorios Leon Farma S.A.

Schizophrenia

Not recruiting

Relative Bioavailability of LY03010 versus Paliperidone Palmitate (with Risperidone background) in Healthy Volunteers for Schizophrenia

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · Healthy volunteers
  • Substances:Risperidone
  • Sponsor:Geneora Pharma (Shijiazhuang) Co. Ltd.

Aplastic anaemia+1

Not recruiting

A study to compare the absorption of eltrombopag olamine in healthy volunteers to ensure the tablets work the same way for patients with thrombocytopenia or aplastic anemia.

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · Healthy volunteers
  • Substances:Eltrombopag olamine
  • Sponsor:Bluepharma Industria Farmaceutica S.A.

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Maia

What the registry says about research in the country

01 Cardiovascular Research

Ongoing clinical trials focusing on atherosclerotic cardiovascular disease in patients with end-stage kidney disease. Research aims to evaluate innovative treatment approaches for reducing inflammatory markers in dialysis patients.

  • Cardiovascular outcomes in ESKD patients
  • Inflammatory biomarker reduction
  • Dialysis patient care optimization

These studies investigate the relationship between inflammatory markers and cardiovascular health in patients undergoing maintenance dialysis, potentially leading to improved treatment strategies for this vulnerable population.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.